Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Danxing antifibrillation granule is a Traditional Chinese Medicine (TCM) herbal formulation developed by the Affiliated Hospital of Shaanxi University of Chinese Medicine for the treatment of Parkinson's disease. It is administered as an oral granule, often in combination with standard antiparkinsonian medications. The prescription is currently being evaluated in clinical trials in China to assess its impact on clinical symptoms and to investigate its underlying biological mechanisms using transcriptomic analysis. As a multi-component botanical product, it likely exerts its effects through multiple pathways involved in neuroprotection and motor symptom management.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Danxing antifibrillation granule.